no code implementations • 19 Oct 2020 • Albert Weichselbraun, Philipp Kuntschik, Sandro Hörler
Performing company valuations within the domain of biotechnology, pharmacy and medical technology is a challenging task, especially when considering the unique set of risks biotech start-ups face when entering new markets.